| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
© 2002 AlphaMed Press
Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?
Departments of Medicine and Cancer Biology, and Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
Correspondence: Carlos L. Arteaga, M.D., Departments of Medicine and Cancer Biology, and Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232-6307, USA. Telephone: 615-936-3524; Fax: 615-936-1790; e-mail: Carlos.Arteaga{at}mcmail.vanderbilt.edu
The epidermal growth factor receptor (EGFR) is a rational target for antitumor strategies. EGFR signaling causes increased proliferation, decreased apoptosis, and enhanced tumor cell motility and neo-angiogenesis. The EGFR is expressed or highly expressed in a variety of human tumors of epithelial origin. ZD1839 (IressaTM) is an orally active, selective EGFR tyrosine kinase inhibitor, which blocks signal transduction pathways implicated in proliferation and survival of cancer cells.
The lack of a consistent method of evaluating levels of EGFR has caused a disparity in reports of the EGFR as a prognostic factor; however, for some tumors, EGFR is a strong prognostic indicator associated with more aggressive disease and reduced survival. So far, no clear association between EGFR levels and response to EGFR-targeted agents has been found. Preclinical studies with ZD1839 have noted a relationship between the two in some cases, but not others.
EGFR signaling may be increased by a number of mechanisms in addition to high expression levels of EGFR, including receptor mutations, heterodimerization with other members of this receptor family such as HER2 (erbB2), increased expression of (autocrine/ paracrine) ligands, and alterations in molecules that control receptor signaling output. Each of these components could be assessed to give an indication of the magnitude of EGFR signal amplification. Evaluation of signaling components downstream from EGFR should provide information on the activation of the EGFR pathway.
Until EGFR-based assays predictive of a response to receptor-targeted therapies are available, there is no clear justification for stratifying patients by EGFR status or excluding patients with low EGFR levels from trials with ZD1839 or other EGFR inhibitors.
Related articles in The Oncologist:
- Moving Forward with Capecitabine: A Glimpse of the Future
- Laura Biganzoli, Miguel Martin, and Chris Twelves
The Oncologist 2003 8: 124.[Full Text]
This article has been cited by other articles:
 |
|
 |
|
  S. Adachi, M. Shimizu, Y. Shirakami, J. Yamauchi, H. Natsume, R. Matsushima-Nishiwaki, S. To, I.B. Weinstein, H. Moriwaki, and O. Kozawa (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells Carcinogenesis, September 1, 2009; 30(9): 1544 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Z. Rappoport and S. M. Simon Endocytic trafficking of activated EGFR is AP-2 dependent and occurs through preformed clathrin spots J. Cell Sci., May 1, 2009; 122(9): 1301 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kaulfuss, P. Burfeind, J. Gaedcke, and J.-G. Scharf Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis Mol. Cancer Ther., April 1, 2009; 8(4): 821 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Narayan, J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler, and N. J. Maihle Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells Cancer Res., March 15, 2009; 69(6): 2191 - 2194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Bialkowska, Y. Du, H. Fu, and V. W. Yang Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening Mol. Cancer Ther., March 1, 2009; 8(3): 563 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Felip, F. Rojo, M. Reck, A. Heller, B. Klughammer, G. Sala, S. Cedres, S. Peralta, H. Maacke, D. Foernzler, et al. A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy Clin. Cancer Res., June 15, 2008; 14(12): 3867 - 3874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Diagaradjane, J. M. Orenstein-Cardona, N. E. Colon-Casasnovas, A. Deorukhkar, S. Shentu, N. Kuno, D. L. Schwartz, J. G. Gelovani, and S. Krishnan Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe Clin. Cancer Res., February 1, 2008; 14(3): 731 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Croce Oncogenes and Cancer N. Engl. J. Med., January 31, 2008; 358(5): 502 - 511. [Full Text] [PDF]
|
|
|
|
|
|
S. Buvinic, M. Bravo-Zehnder, J. L. Boyer, J. P. Huidobro-Toro, and A. Gonzalez Nucleotide P2Y1 receptor regulates EGF receptor mitogenic signaling and expression in epithelial cells J. Cell Sci., December 15, 2007; 120(24): 4289 - 4301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review Ann. Onc., August 1, 2006; 17(8): 1185 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hirsch, Y. Shen, and W. J. Wu Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of cdc42. Cancer Res., April 1, 2006; 66(7): 3523 - 3530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kong, P. Leboucher, R. Leek, V. Calleja, S. Winter, A. Harris, P. J. Parker, and B. Larijani Prognostic value of an activation state marker for epidermal growth factor receptor in tissue microarrays of head and neck cancer. Cancer Res., March 1, 2006; 66(5): 2834 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. T. Ihle, G. Paine-Murrieta, M. I. Berggren, A. Baker, W. R. Tate, P. Wipf, R. T. Abraham, D. L. Kirkpatrick, and G. Powis The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts Mol. Cancer Ther., September 1, 2005; 4(9): 1349 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bianco, T. Troiani, G. Tortora, and F. Ciardiello Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S159 - S171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson Development of strategies for the use of anti-growth factor treatments Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P M Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr. Relat. Cancer, December 1, 2004; 11(4): 689 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Young, G. G. Schwartz, L. Wang, D. P. Jamieson, L. W. Whitlatch, J. N. Flanagan, B. L. Lokeshwar, M. F. Holick, and T. C. Chen The prostate 25-hydroxyvitamin D-1{alpha}-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D Carcinogenesis, June 1, 2004; 25(6): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ono, A. Hirata, T. Kometani, M. Miyagawa, S.-i. Ueda, H. Kinoshita, T. Fujii, and M. Kuwano Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation Mol. Cancer Ther., April 1, 2004; 3(4): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Giaccone, R. S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, V. Miller, R. B. Natale, J. H. Schiller, J. von Pawel, A. Pluzanska, et al. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial--INTACT 1 J. Clin. Oncol., March 1, 2004; 22(5): 777 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, G. Giaccone, J. H. Schiller, R. B. Natale, V. Miller, C. Manegold, G. Scagliotti, R. Rosell, I. Oliff, J. A. Reeves, et al. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial--INTACT 2 J. Clin. Oncol., March 1, 2004; 22(5): 785 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Cattley and B. R. Radinsky Cancer Therapeutics: Understanding the Mechanism of Action Toxicol Pathol, January 1, 2004; 32(1_suppl): 116 - 121. [Abstract] [PDF]
|
|
|
|
|
|
T. T. Junttila, M. Laato, T. Vahlberg, K.-O. Soderstrom, T. Visakorpi, J. Isola, and K. Elenius Identification of Patients with Transitional Cell Carcinoma of the Bladder Overexpressing ErbB2, ErbB3, or Specific ErbB4 Isoforms: Real-Time Reverse Transcription-PCR Analysis in Estimation of ErbB Receptor Status from Cancer Patients Clin. Cancer Res., November 1, 2003; 9(14): 5346 - 5357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Y Liu and S. Seen Gefitinib Therapy for Advanced Non-Small-Cell Lung Cancer Ann. Pharmacother., November 1, 2003; 37(11): 1644 - 1653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Baselga Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy Oncologist, August 15, 2002; 7(90004): 2 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst and M. S. Kies ZD1839 (IressaTM) in Non-Small Cell Lung Cancer Oncologist, August 15, 2002; 7(90004): 9 - 15. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
Copyright © 2002 by AlphaMed Press.